The Pro Medicus Ltd (ASX: PME) share price is up after revealing a large US contract win.
Pro Medicus describes itself as a leading healthcare informatics company. It provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups. Some of its services include radiology information systems (RIS) and picture archiving and communication systems (PACS).
$128 million US contract win
Pro Medicus announced it has signed a 10-year contract worth A$128 million with NYC Health + Hospitals.
NYC Health + Hospitals is the nation’s largest municipal healthcare delivery system in the US, delivering care for New Yorkers. It has 11 hospitals, 29 Gotham health centres and five long-term care centres, as well as 45,000 healthcare professionals.
The company said that this is based on a transactional licensing model, it will see the company’s cloud-based Visage 7 Enterprise Imaging Platform, including Viewer, Workflow and Open Archive to be implemented throughout NYC Health +Hospitals. providing a unified diagnostic imaging platform.
Visage will complete migration from NYC Health + Hospitals legacy PACS archives to Visage 7 Open Archive. Visage 7 will also provide enterprise distribution of images integrated to NYC Health + Hospitals’ electronic health record (EHR).
Pro Medicus said that planning for the rollout is to commence immediately and will be based on Visage’s cloud-based implementation process, with the go-live targeted for late in the third quarter of the 2027 calendar year. In other words, it’s expected to be late in the quarter of the three months to September 2027, being the first quarter of FY27.
Final thoughts on the Pro Medicus share price
Clearly, the business continues to win impressive contracts with important clients and are locking in significant revenue and earnings growth in the medium-term.
The fact it’s capturing these huge clients despite the worries of AI shows clients want to work with high-quality software providers that have a trusted and proven reputation.
As a shareholder, I’m happy to see the progress the company is achieving and I’m hoping to see good earnings growth in the coming years, partially thanks to its very high EBIT margin of close to 75%.





